Software as a Medical Device FDA Guidance: What Manufacturers Need to Know

Software as a Medical Device (SaMD) plays an important role in healthcare technology, from standalone applications to software that supports connected medical devices. As these products become more complex, FDA reviewers continue to place greater emphasis on software safety, effectiveness, cybersecurity, and supporting documentation.

For manufacturers, software as a medical device FDA guidance provides more than a submission reference. It helps define the evidence reviewers expect to see when evaluating whether software is appropriately designed, tested, validated, and maintained.

Why FDA Guidance Matters for Software as a Medical Device (SaMD)

Software-based devices receive different scrutiny than many traditional devices because software can change quickly. Updates, new features, cybersecurity patches, and algorithm changes may all affect device performance or risk.

FDA reviewers evaluate more than whether the software works. They assess how the software was developed, how risks were identified, how testing was performed, and whether the documentation supports the device’s intended use.

Software-enabled and software-only medical devices continue to expand across diagnostics, monitoring, clinical decision support, patient engagement, and connected care. This growth has increased the need for clear SaMD regulation and practical FDA software review expectations.

Manufacturers should consider FDA guidance early in development rather than waiting until submission preparation. Early planning helps teams align product claims, software requirements, testing, cybersecurity, and documentation before review begins.

Many SaMD submissions face delays because documentation does not clearly support the software’s intended use or risk profile. Common challenges include incomplete software files, unclear claims, weak traceability, missing cybersecurity evidence, and inconsistent testing documentation.

A proactive approach to medical device regulatory compliance⁠ can help manufacturers identify these gaps before submission.

Key FDA Guidance Areas That Impact SaMD Submissions

SaMD submissions often involve more than one FDA guidance document. Reviewers may evaluate software documentation, lifecycle processes, risk management, cybersecurity, clinical performance, and AI/ML considerations within the same submission.

Software Documentation Requirements

FDA reviewers expect documentation that clearly explains what the software does, how it is structured, and how it supports the device’s intended use. This may include software requirements, architecture, design information, validation evidence, and traceability.

Software Lifecycle Processes

Software lifecycle documentation should show how the product was developed, tested, released, maintained, and controlled. Reviewers look for evidence that software activities were performed under established quality processes and design controls.

Cybersecurity Expectations

Cybersecurity is a major area of review for connected and software-based devices. Manufacturers should document security risks, controls, testing, vulnerability management, and update processes.

Risk Management

Risk management documentation should connect software hazards, mitigations, verification activities, and residual risk conclusions. Reviewers use this evidence to assess whether software-related risks have been appropriately controlled.

Clinical and Performance Evidence

Depending on the intended use, manufacturers may need to provide clinical or performance evidence showing that the software performs reliably under expected conditions and supports its stated claims.

AI/ML Considerations

AI-enabled software may require additional documentation related to model validation, performance monitoring, change management, and data-related risks. Manufacturers preparing these submissions may need AI/ML FDA 510(k) documentation⁠ that aligns technical evidence with FDA expectations.

Documentation FDA Reviewers Expect to See in SaMD Submissions

FDA reviewers rely on documentation to understand the software, evaluate safety and effectiveness, and confirm that testing supports the device’s intended use. Strong documentation should be clear, complete, traceable, and consistent across the full submission.

• Software Requirements Documentation: Software requirements define what the device is intended to do. They should be specific, testable, and aligned with the device’s intended use and performance claims.
• Architecture Documentation: Architecture documentation explains the software structure, major components, interfaces, data flow, and system interactions. This helps reviewers understand how the software operates and how design decisions support performance and risk control.
• Risk Management Files: Risk management files should document hazards, risk evaluations, mitigations, verification of controls, and residual risk. These files should connect clearly to requirements and testing evidence.
• Verification and Validation Evidence: Verification and validation evidence shows that the software was built correctly and performs as intended. This may include test plans, protocols, results, acceptance criteria, defect resolution, and regression testing.
• Traceability Documentation: Traceability connects requirements, risks, design outputs, and testing. Strong traceability helps reviewers follow the evidence from intended use through final validation.
• Cybersecurity Documentation: Cybersecurity documentation should support the manufacturer’s security approach, including risk assessments, threat modeling, vulnerability management, secure development practices, and update procedures.

Consistency matters across all submission materials. Differences between software descriptions, test records, risk files, and cybersecurity documentation can lead to FDA questions.

Common SaMD Submission Gaps That Trigger FDA Questions

Software submissions often receive Additional Information (AI) requests when FDA reviewers cannot clearly evaluate the submitted evidence. These requests do not necessarily indicate that a device is unsafe or ineffective, but they can delay the review process. Some of the most common documentation gaps include:

• Incomplete software documentation: Missing or limited software documentation can make it difficult for reviewers to understand the device’s functionality, architecture, or development controls.
• Weak traceability: If software requirements cannot be connected to identified risks and verification activities, reviewers may question whether critical functions have been adequately tested.
• Unclear intended use descriptions: Intended use statements should be clear and consistent throughout the submission. If claims differ across documents, FDA may request clarification.
• Missing risk assessments: Risk management documentation should demonstrate how hazards were identified, evaluated, mitigated, and verified.
• Insufficient cybersecurity evidence: FDA may request additional information if the submission does not adequately address threat modeling, vulnerability management, security testing, secure software development practices, or software update procedures.
• Inconsistent testing documentation: Verification and validation documentation should align with software requirements, risk controls, and acceptance criteria.

Organizations preparing software submissions often use 510(k) submission support⁠ to identify documentation gaps before FDA review.

Cybersecurity and Risk Management Expectations for SaMD

Cybersecurity is now a central part of submission readiness for many SaMD and connected medical devices. FDA expects manufacturers to address cybersecurity throughout the software lifecycle rather than treating it as a final submission activity.

Cybersecurity Risk Assessments

Manufacturers should evaluate cybersecurity risks that could affect device safety, effectiveness, data integrity, or availability. These risks should be documented and tied to appropriate controls.

Threat Modeling

Threat modeling helps identify how a device could be targeted or compromised. It also supports risk-based decisions about security controls and testing priorities.

SBOM Requirements

A Software Bill of Materials, or SBOM, documents software components and dependencies. This information supports vulnerability monitoring and lifecycle maintenance.

Vulnerability Management

Manufacturers should document how vulnerabilities will be identified, assessed, addressed, and communicated after release. This is especially important for connected devices and software that relies on third-party components.

Secure Software Development Practices

Secure development practices may include code review, access controls, security testing, update procedures, and monitoring activities. These practices should connect to broader risk management and submission documentation.

QCC helps manufacturers prepare cybersecurity documentation for FDA submissions⁠ that is organized for reviewer evaluation.

How FDA Guidance Is Evolving for AI/ML-Enabled Software

Artificial intelligence (AI) and machine learning (ML) are becoming increasingly common in Software as a Medical Device (SaMD), supporting applications such as diagnostics, image analysis, clinical decision-making, and workflow optimization. Because AI/ML models can evolve over time, FDA expects manufacturers to provide additional evidence demonstrating that the software functions as intended for its target population and clinical use. This includes documenting model validation, performance monitoring, and, when applicable, Predetermined Change Control Plans (PCCPs) that describe how future software modifications will be managed.

Compared to traditional software, AI-enabled SaMD often receives additional regulatory scrutiny because reviewers must evaluate not only current performance, but also how the model may change over time and how associated risks will be managed. Manufacturers should also consider potential bias in training data, model design, and intended use, ensuring these factors are addressed within their broader validation and risk management documentation. Clear, well-organized evidence helps reviewers understand how AI/ML functionality supports the device’s safety, effectiveness, and long-term performance.

Preparing a Submission-Ready SaMD Documentation Package

A smoother FDA review often begins with documentation that is built throughout development, not assembled at the end. Before submitting your application, consider the following best practices:

• Build documentation early. Develop software requirements, architecture documentation, risk management files, cybersecurity documentation, and testing evidence alongside product development. This helps reduce inconsistencies and missing information later in the process.
• Establish traceability. Ensure traceability connects software requirements, identified risks, verification activities, and validation results. Strong traceability makes it easier for FDA reviewers to understand how the submitted evidence supports the device’s safety and effectiveness.
• Align cross-functional teams. Software, regulatory, quality, clinical, and cybersecurity teams should collaborate throughout development. Early alignment helps create documentation that is complete, accurate, and consistent across the submission.
• Review documentation from an FDA reviewer perspective. Before submission, evaluate the documentation as an FDA reviewer would. Look for unclear claims, inconsistent terminology, missing evidence, or documentation gaps that could generate follow-up questions.
• Address known gaps before submission. Resolve documentation deficiencies whenever possible before submitting to the FDA. A well-organized, submission-ready package often reduces review friction, minimizes Additional Information requests, and supports a more efficient review process.

Manufacturers preparing software-based devices may benefit from FDA 510(k) support⁠ that helps organize technical evidence into a clear, reviewer-ready package.

Preparing a SaMD submission or responding to FDA questions? Speak with our regulatory team⁠ to discuss how Quality Commercial Consultants can support your documentation and submission strategy.